Holen Sie sich die Stockscreener-App
3.1768
1.03%
-0.0332
Schlusskurs vom Vortag:
$3.21
Offen:
$3.17
24-Stunden-Volumen:
2,218
Relative Volume:
0.24
Marktkapitalisierung:
$58.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.64M
KGV:
-6.0212
EPS:
-0.5276
Netto-Cashflow:
$-6.76M
1W Leistung:
-2.26%
1M Leistung:
+2.48%
6M Leistung:
-18.12%
1J Leistung:
-44.85%
1-Tages-Spanne:
$3.17
$3.38
1-Wochen-Bereich:
$3.05
$3.47
52-Wochen-Spanne:
$2.56
$6.12
Genenta Science Spa Adr Stock (GNTA) Company Profile
Firmenname
Genenta Science Spa Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GNTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
3.1768 | 61.46M | 0 | -9.64M | -6.76M | -0.5276 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-29 | Fortgesetzt | ROTH MKM | Buy |
| 2022-07-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-13 | Eingeleitet | Maxim Group | Buy |
Genenta Science Spa Adr Aktie (GNTA) Neueste Nachrichten
Genenta Science Reports Reduced Losses and Strengthened Balance Sheet for H1 2025 - TipRanks
Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO - The Globe and Mail
Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Update - MarketBeat
Can Genenta Science S.p.A. (Common Stock) (K5F) stock hold up in economic slowdownGap Down & Community Driven Trade Alerts - newser.com
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Genenta Science (NASDAQ:GNTA) Stock Price Down 1.9%Here's What Happened - MarketBeat
Analyzing Genenta Science S.p.A. Depositary Receipt with multi timeframe chartsWeekly Risk Summary & Short-Term Swing Trade Alerts - newser.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Genenta Science S.p.A. Announces Shareholders’ Meeting for Strategic Amendments - TipRanks
Genenta Science (NASDAQ:GNTA) Trading 7.4% HigherHere's Why - MarketBeat
Real time alert setup for Trinity Capital Inc. performanceJuly 2025 Drop Watch & Capital Protection Trading Alerts - Newser
Using data filters to optimize entry into Genenta Science S.p.A. Depositary ReceiptJuly 2025 News Drivers & High Accuracy Investment Signals - Newser
Assembly Biosciences Inc. stock trend outlook and recovery pathGDP Growth & Safe Capital Growth Tips - Newser
Genenta Science S.p.A. to Terminate Dedicated Suite Agreement with AGC Biologics - MSN
Genenta Science (NASDAQ:GNTA) Trading 7.4% Higher – Time to Buy? - Defense World
Will Genenta Science S.p.A. Depositary Receipt stock go up soonJuly 2025 News Drivers & Entry and Exit Point Strategies - Newser
How moving averages guide Genenta Science S.p.A. Depositary Receipt tradingTrade Signal Summary & Safe Capital Investment Plans - Newser
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
Applying sector rotation models to Altice USA Inc.Free Risk Managed Intraday Trade Alerts - Newser
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
Genenta Science stock maintains Buy rating as Temferon shows promise in GBM - Investing.com
Genenta secures $21.9 million for cancer drug trial - Investing.com
Oncology Breakthroughs: How Cancer Research Is Advancing in 202527.02.25News - Ariva
Genenta Science announces amendment to pact with AGC Biologics - Yahoo Finance
Genenta Science Enhances Manufacturing Agreement with AGC Biologics - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
10 Best Italian Stocks To Buy Now - Yahoo Finance
Trading Halts Explained - MarketBeat
Stock Market Alerts - MarketBeat
Finanzdaten der Genenta Science Spa Adr-Aktie (GNTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):